NCT05905926 ENROLLING BY INVITATION Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
Ardelyx n=150
NCT06413368 RECRUITING Maralixibat in Patients With Cystic Fibrosis and Constipation
Children's Hospital Los Angeles n=20
NCT07522255 NOT YET RECRUITING Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders
Mahidol University n=78
NCT06810167 RECRUITING Assessing Tenapanor as a Treatment of CF-related Constipation.
Massachusetts General Hospital n=25
NCT07382167 RECRUITING A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
Ardelyx n=692
NCT07277907 RECRUITING Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation
Third Military Medical University n=346
NCT05643534 ACTIVE NOT RECRUITING Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
Ardelyx n=180
NCT05519683 RECRUITING Home Transcutaneous Electrical Acustimulation (TEA)
University of Michigan n=160
NCT04547816 RECRUITING Efficacy of Conservative Treatment of Functional Defecatory Disorders in Females With Pelvic Organ Prolapse
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology n=100
NCT06836024 NOT YET RECRUITING A Trial of Actazin Versus PEG 3350 for Maintenance Therapy in Children With Constipation
Hamilton Health Sciences Corporation n=60
NCT06740422 NOT YET RECRUITING Xuanhuang Runtong Tablet in the Treatment of Constipation (Yin-deficiency Type)
Beijing Hospital of Traditional Chinese Medicine n=300
NCT06351995 ACTIVE NOT RECRUITING Neostigmine and Glycopyrrolate by Iontophoresis
James J. Peters Veterans Affairs Medical Center n=6
NCT04166058 COMPLETED Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
AbbVie n=381
NCT05652205 COMPLETED A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
AbbVie n=123
NCT04026113 COMPLETED Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
AbbVie n=438
NCT02809105 COMPLETED A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation
Astellas Pharma Inc n=186
NCT02316899 COMPLETED Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
Astellas Pharma Inc n=500
NCT05151328 COMPLETED Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. n=648
NCT04759833 TERMINATED A Study of Prucalopride For Functional Constipation in Children and Teenagers
Takeda n=175
NCT02822508 COMPLETED A Safety and Efficacy Evaluation of BLI801 Laxative in Adults Experiencing Non-Idiopathic Constipation
Braintree Laboratories n=434
NCT05341180 COMPLETED Efficacy of Polyethylene Glycol vs Lactulose With Isabgol in Acute Fissure-in-Ano: PEGASIS Trial
All India Institute of Medical Sciences, Bhubaneswar n=144
NCT04433390 COMPLETED Effect of Naloxegol on Postoperative Ileus in Patients Undergoing Cardiac Surgery
CMC Ambroise Paré n=305
NCT01117051 TERMINATED Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation
Shire n=174
NCT01147926 COMPLETED Evaluation of Prucalopride in Male Subjects With Chronic Constipation.
Shire n=374
NCT01330381 COMPLETED Prucalopride in Pediatric Subjects With Functional Constipation
Shire n=215
NCT02705378 WITHDRAWN The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit
Massachusetts General Hospital
NCT03573908 COMPLETED A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Ironwood Pharmaceuticals, Inc. n=614
NCT02727751 COMPLETED A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
Ardelyx n=312
NCT02481947 COMPLETED A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults
Braintree Laboratories n=459
NCT02819297 COMPLETED BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults
Braintree Laboratories n=1,020
NCT02042183 COMPLETED Lubiprostone in Children With Functional Constipation
Sucampo Pharma Americas, LLC n=606
NCT02819310 COMPLETED An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults
Braintree Laboratories n=330
NCT04451096 COMPLETED Probiotics-prebiotic Fiber Therapy in Parkinson's Disease Patients With Constipation
National University of Malaysia n=48
NCT02766777 COMPLETED Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation
Sucampo Pharma Americas, LLC n=87
NCT02686138 COMPLETED A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C
Ardelyx n=593
NCT02621892 COMPLETED A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Ardelyx n=606
NCT01923428 COMPLETED The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
Ardelyx n=356
NCT02138136 COMPLETED Lubiprostone for Children With Constipation
Sucampo Pharma Americas, LLC n=419
NCT03097861 COMPLETED Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo
Sucampo Pharma Americas, LLC n=552
NCT00936884 COMPLETED Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation
Bausch Health Americas, Inc. n=50
NCT01982240 COMPLETED 12-Week Study of Plecanatide for CIC (The CIC3 Study)
Bausch Health Americas, Inc. n=1,394
NCT01993875 COMPLETED Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
Mallinckrodt n=164
NCT00804141 COMPLETED Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation
Bausch Health Americas, Inc. n=1,040
NCT01186770 COMPLETED A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
Bausch Health Americas, Inc. n=804
NCT01919697 COMPLETED Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)
Bausch Health Americas, Inc. n=2,370
NCT02387359 COMPLETED The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
Bausch Health Americas, Inc. n=1,054
NCT02493452 COMPLETED Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
Bausch Health Americas, Inc. n=1,135
NCT01429987 COMPLETED The Plecanatide Chronic Idiopathic Constipation (CIC) Study
Bausch Health Americas, Inc. n=951
NCT02122471 COMPLETED 12-Week Study of Plecanatide for CIC (The National CIC3 Study)
Bausch Health Americas, Inc. n=1,410
NCT02729909 COMPLETED Lubiprostone for Chronic Idiopathic Constipation Treatment
Takeda n=211
NCT03885973 COMPLETED Lactobacillus Plantarum IS 10560 Supplementation in Women With Functional Constipation
Fakultas Kedokteran Universitas Indonesia n=76
NCT00765999 COMPLETED An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
Forest Laboratories n=1,559
NCT03829358 COMPLETED The Role of Probiotics in Improving Quality of Life in Women With Functional Constipation
Fakultas Kedokteran Universitas Indonesia n=76
NCT02695719 COMPLETED Lubiprostone for Treatment of Chronic Idiopathic Constipation
Takeda n=156
NCT01901341 TERMINATED The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=44
NCT01901302 TERMINATED Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=61
NCT01696643 TERMINATED Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=1,407
NCT01901328 TERMINATED Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=49
NCT01438567 COMPLETED A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
Mundipharma Research GmbH & Co KG n=270
NCT02194972 COMPLETED Clinical Effects of Soluble Dietary Fiber Supplementation
Nanjing PLA General Hospital n=80
NCT02651155 COMPLETED Lubiprostone for the Treatment of Chronic Idiopathic Constipation
Takeda n=204
NCT01965652 COMPLETED Long Term Safety of Naldemedine
Shionogi n=1,246
NCT00730171 COMPLETED An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
Ironwood Pharmaceuticals, Inc. n=1,743
NCT02961556 COMPLETED General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation
EA Pharma Co., Ltd. n=39
NCT03100851 COMPLETED Effect of Probiotic on Constipation
China Agricultural University n=62
NCT02291679 COMPLETED Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Ironwood Pharmaceuticals, Inc. n=1,223
NCT01469819 COMPLETED Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation
Texas Tech University Health Sciences Center, El Paso n=37
NCT01447849 COMPLETED Lubiprostone and Mucus Secretion in Patients With Chronic Constipation
Texas Tech University Health Sciences Center, El Paso n=40
NCT01993940 COMPLETED Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation
Shionogi n=553
NCT01965158 COMPLETED Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation
Shionogi n=547
NCT01116206 COMPLETED An Efficacy and Safety Study of Prucalopride in Participants With Chronic Constipation
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. n=507
NCT01151878 COMPLETED Glucomannan for Childhood Functional Constipation.
Medical University of Warsaw n=92
NCT01395524 COMPLETED A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca n=302
NCT01880424 COMPLETED A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
AstraZeneca n=1,722
NCT02138851 COMPLETED The Effects of a Ficus Carica in Subjects With Functional Constipation
Chonbuk National University Hospital n=80
NCT01895543 COMPLETED Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation
Ferring Pharmaceuticals n=411
NCT01642914 COMPLETED Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating
Forest Laboratories n=487
NCT01411501 COMPLETED Efficacy and Safety of Acupuncture for Functional Constipation
Guang'anmen Hospital of China Academy of Chinese Medical Sciences n=684
NCT01827592 TERMINATED 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation
Ferring Pharmaceuticals n=376
NCT01833065 TERMINATED Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
Ferring Pharmaceuticals n=314
NCT01014559 TERMINATED Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients
Mundipharma SAS n=225
NCT02292459 WITHDRAWN Efficacy and Safety of Polyethylene Glycol 3350 (PEG 3350) for Relief of Constipation (MK-8114-005)
Bayer
NCT01323790 COMPLETED Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca n=700
NCT01309841 COMPLETED Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca n=652
NCT01384292 TERMINATED Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
AstraZeneca n=14
NCT02073006 COMPLETED A Study to Evaluate the Effects of a Natural Supplement in Adults With Chronic Functional Constipation
Atlantia Food Clinical Trials n=70
NCT01607060 COMPLETED Impact of Laxative Therapy With Lactulose in the Evolution of Organ Dysfunction in Critically Ill Patients.
Federal University of São Paulo n=88
NCT01837940 COMPLETED Efficacy of a Dietary Supplementation With Lactobacillus Reuteri for Digestive Health in an Elderly Population
Örebro University, Sweden n=290
NCT01336205 COMPLETED Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca n=844
NCT01463293 COMPLETED B. Lactis HN019 for Functional Constipation
Fonterra Research Centre n=224
NCT00990951 SUSPENDED Study of Efficacy of Association of Senna Alexandrina Mill and Associations on Functional Intestinal Constipation
Marjan Industria e Comercio ltda n=80
NCT01674530 COMPLETED Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation
Dr. Reddy's Laboratories Limited n=909
NCT01809587 COMPLETED IQP-PO-101 for the Regulation of Bowel Movement Frequency
InQpharm Group n=50
NCT00938717 COMPLETED Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Ironwood Pharmaceuticals, Inc. n=805
NCT01870700 COMPLETED Lactobacillus Reuteri in Adult With Functional Chronic Constipation
Catholic University, Italy n=40
NCT00742872 TERMINATED Randomized Trial of Mosapride Versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome
American University of Beirut Medical Center n=41
NCT00994851 COMPLETED Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
Sanofi n=96
NCT00765882 COMPLETED Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation
Forest Laboratories n=633
NCT00948818 COMPLETED Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
Forest Laboratories n=803
NCT00730015 COMPLETED Trial of Linaclotide in Patients With Chronic Constipation
Ironwood Pharmaceuticals, Inc. n=643
NCT00931853 COMPLETED Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).
Sanofi n=117
NCT01474499 COMPLETED A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
Ferring Pharmaceuticals n=300
NCT01251822 COMPLETED Comparator Study of PEG 3350 Versus Prucalopride in Females With Chronic Constipation
Norgine n=240
NCT01372423 COMPLETED Evaluation of Clinical Equivalence Between Two Lubiprostone Products
Anchen Pharmaceuticals, Inc n=808
NCT00992576 COMPLETED Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of Pain
Mundipharma Research GmbH & Co KG n=600
NCT00571896 COMPLETED The Use of SennaS for Prevention of Post-operative Constipation After Urogynecologic Surgery
Hartford Hospital n=72
NCT01161784 COMPLETED The Effects of a Probiotic Fermented Milk on Functional Constipation in Adults
IMU University, Malaysia n=100
NCT00746200 COMPLETED Acupuncture for Chronic Constipation
National Taiwan University Hospital n=80
NCT00745147 COMPLETED Comparison of TCM and Laxatives for Adults With Chronic Constipation
National Taiwan University Hospital n=93
NCT00796354 COMPLETED Constipation Associated With Irritable Bowel Syndrome (IBS-C)
Norgine n=210